128 related articles for article (PubMed ID: 37442742)
21. Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.
Auclin E; Bourillon C; De Maio E; By MA; Seddik S; Fournier L; Auvray M; Dautruche A; Vano YA; Thibault C; Joly F; Brunereau L; Gomez-Roca C; Chevreau C; Elaidi R; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):350-355. PubMed ID: 28216276
[TBL] [Abstract][Full Text] [Related]
22. No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.
Miyazaki A; Miyake H; Harada K; Fujisawa M
Anticancer Res; 2015 May; 35(5):3067-73. PubMed ID: 25964597
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.
Poprach A; Rumanova K; Lakomý R; Chloupková R; Stanik M; Pokrivcak T; Kiss I; Slaby O; Studentova H; Melichar B; Juracek J; Fiala O; Kopecky J; Kopeckova K; Zemanova M; Buchler T
Urol Oncol; 2019 Apr; 37(4):294.e1-294.e8. PubMed ID: 30683455
[TBL] [Abstract][Full Text] [Related]
24. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of sarcopenia and sarcopenic obesity in patients affected by oral squamous cell carcinoma: A retrospective single-center study.
Bonavolontà P; Improta G; Dell'Aversana Orabona G; Goglia F; Abbate V; Sorrentino A; Piloni S; Salzano G; Iaconetta G; Califano L
J Craniomaxillofac Surg; 2023 Jan; 51(1):7-15. PubMed ID: 36739189
[TBL] [Abstract][Full Text] [Related]
26. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma.
Taguchi S; Akamatsu N; Nakagawa T; Gonoi W; Kanatani A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Homma Y
Clin Genitourin Cancer; 2016 Jun; 14(3):237-43. PubMed ID: 26337653
[TBL] [Abstract][Full Text] [Related]
27. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
28. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of sarcopenia and decreased relative dose intensity during the initial two cycles of first-line sunitinib for metastatic renal cell carcinoma.
Lee CH; Ku JY; Seo WI; Park YJ; Chung JI; Kim W; Park TY; Ha HK
J Chemother; 2021 Jul; 33(4):245-255. PubMed ID: 33412998
[TBL] [Abstract][Full Text] [Related]
30. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.
Herrmann T; Mione C; Montoriol PF; Molnar I; Ginzac A; Durando X; Mahammedi H
Oncology; 2022; 100(2):114-123. PubMed ID: 34999587
[TBL] [Abstract][Full Text] [Related]
31. Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.
Shimizu R; Honda M; Teraoka S; Yumioka T; Yamaguchi N; Kawamoto B; Iwamoto H; Morizane S; Hikita K; Takenaka A
Int J Clin Oncol; 2022 Jan; 27(1):175-183. PubMed ID: 34606022
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the controlling nutritional status score in patients with metastatic renal cell carcinoma diagnosed before an era of first-line immune-oncology combination therapies.
Sekiya K; Ito M; Takemura K; Suzuki H; Kobayashi S; Koga F
Jpn J Clin Oncol; 2021 Oct; 51(10):1570-1576. PubMed ID: 34075403
[TBL] [Abstract][Full Text] [Related]
33. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
34. Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.
Schmeusser BN; Midenberg E; Palacios AR; Ali AA; Patil DH; Higgins M; Nabavizadeh R; Croll B; Williams M; Sheehy J; Zheng B; Narayan VM; Joshi SS; Ogan K; Psutka SP; Bilen MA; Master VA
Clin Genitourin Cancer; 2023 Aug; 21(4):475-482.e4. PubMed ID: 37210313
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
36. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
Miyake M; Morizawa Y; Hori S; Marugami N; Shimada K; Gotoh D; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K
BMC Cancer; 2017 Mar; 17(1):237. PubMed ID: 28359307
[TBL] [Abstract][Full Text] [Related]
38. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract][Full Text] [Related]
39. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan NC; Alan Ö; Başoğlu Tüylü T; Akın Telli T; Arıkan R; Çiçek FC; Ercelep Ö; Öztürk MA; Alsan Çetin İ; Ergelen R; Tinay İ; Akgül Babacan N; Kaya S; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jul; 26(5):1147-1155. PubMed ID: 31793376
[TBL] [Abstract][Full Text] [Related]
40. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
Parosanu AI; Pirlog CF; Slavu CO; Stanciu IM; Cotan HT; Vrabie RC; Popa AM; Olaru M; Iaciu C; Bratu LI; Baicoianu IF; Moldoveanu O; Baston C; Nițipir C
Curr Oncol; 2023 Feb; 30(2):2457-2464. PubMed ID: 36826148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]